Directors from the 25 largest liver transplant programs along with speakers with recognized expertise attended. The purposes of this conference were to propose indications for SLK, to establish a prospective data registry and, most importantly, to recommend standard listing criteria for these patients. Scientific registry of transplant recipients data, and single center data regarding chronic kidney disease (CKD) and acute kidney injury (AKI) in conjunction with liver failure as a basis for SLK was presented and discussed. The consensus was that Regional Review Boards (RRB) should determine listing for SLK, as with other MELD exceptions, with automatic approval for: (i) End-stage renal disease with cirrhosis and symptomatic portal hypertension or hepatic vein wedge pressure gradient ≥ 10 mm Hg (ii) Liver failure and CKD with GFR ≤ 30 mL/min (iii) AKI or hepatorenal syndrome with creatinine ≥ 2.0 mg/dL and dialysis ≥ 8 weeks (iv) Liver failure and CKD and biopsy demonstrating > 30% glomerulosclerosis or 30% fibrosis. The RRB would evaluate all other requests to determine appropriateness. 
Introduction

One of the greatest challenges facing orthotopic liver transplantation (OLT) today is pre and posttransplant renal dysfunction. Serum creatinine is a predictor of posttransplant outcome, and kidney injury is the greatest determinant of mortality (1,2). Since the institution of the model of endstage liver disease (MELD) system in 2002, the number of simultaneous liver-kidney transplants (SLK) has increased over 300%. The primary issue is to balance benefit and utility to assure that patient and graft survival is optimized while limiting unnecessary transplants. A recent consensus conference convened to establish guidelines for evaluation, listing and transplantation of patients with end-stage liver disease (ESLD) and renal failure. A second purpose was to establish a registry to study criteria important in determining propriety of SLK. Finally, this group was charged with proposing standard listing criteria for SLK to United Network for Organ Sharing (UNOS).
Scientific Registry of Transplant Recipients (SRTR) Data (3)
Conferees
Evaluation of the Prospective SLK Candidate
All liver transplant candidates should be evaluated according to the algorithm published from the first consensus conference (2). Prospective recipients should be categorized as having AKI or chronic kidney disease (CKD) determined by the definitions developed by the AKI Network and Acute Dialysis Quality Initiative Group and the National Kidney Foundation (NKF) guidelines (4-8). Once a patient is on the waiting list, kidney function should be assessed at least at the time points required to confirm MELD status. Cystatin C is a more accurate marker of renal function than
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serum creatinine, however it is not universally available and is not part of the MELD assessment paradigm (9).
Intrarenal fibrosis is associated with progression to ESRD asymptomatic for years, and thus may be well-served by receiving KTA (13) . The determination of SLK versus KTA must be based on liver histology and signs of portal hypertension with wedge hepatic vein pressure being the gold standard (14) . A proposed algorithm for selection for SLK listing in these patients is demonstrated in Figure 4 . (19) . There was also no evidence that LTA followed by kidney transplant was deleterious. These findings corroborated SRTR data, demonstrating that survival in the setting of sequential kidney after liver transplantation was similar to that after SLK (20, 21) . 
Special Patient Considerations for SLK
In addition to the degree of kidney impairment, the duration of pre-OLT kidney dysfunction may predict posttransplant kidney function (17). While most LTA recipients with pretransplant kidney dysfunction do not progress to consideration for kidney transplantation (eGFR < 20 mL/min) by 3 years posttransplant, there is a significant number who will. (18). Sixty OLT recipients with kidney impairment pretransplant were compared according to duration of dysfunction (< or > 12 weeks). Pretransplant kidney dysfunction greater than 12 weeks strongly predicted a posttransplant eGFR <20 mL/min. This endpoint was reached in eight (13%) patients, of whom six were in the cohort
A study examining kidney outcomes in SLK recipients with HRS, demonstrated no differences in posttransplant dialysis requirement, or three-year survival between patients with (n = 22) and without (n = 76) HRS (22
Net Benefit
There was significant discussion of net benefit and the ethical considerations of SLK with regard to taking potential 
